Meta-analyses of studies on SGLT2 inhibitors in T2DM have shown reductions in HbA1c of approximately 0.5% to 1% (6–11 mmol/mol) [28,29]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.